(2R)-2-({(2E)-3-[(2R,3R)-3-{[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl}-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl}oxy)-3-(3,4-dihydroxyphenyl)propanoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 2-芳基苯并呋喃类黄酮
• 英文名称: (2R)-2-({(2E)-3-[(2R,3R)-3-{[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl}-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl}oxy)-3-(3,4-dihydroxyphenyl)propanoic acid
• 英文别名: (2R)-2-[(E)-3-[(2R,3R)-3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid
• 化学式: C₃₆H₃₀O₁₆
• 分子量: 718.6
• InChiKey: SNKFFCBZYFGCQN-RDHSGEKBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  52
• 可旋转键数：
  14
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  278
• 氢给体数：
  9
• 氢受体数：
  16

文献信息

• CD36 INHIBITION TO CONTROL OBESITY AND INSULIN SENSITIVITY
  申请人：Cho Sunghee

  公开号：US20130116308A1

  公开（公告）日：2013-05-09

  The disclosure relates to the therapeutic utility of CD36 antagonists to reduce body weight, inhibit fat accumulation and especially visceral fat accumulation, improve insulin sensitivity, lower blood glucose levels, and treat and prevent metabolic syndrome, pre-diabetes and diabetes, and lower plasma cholesterol levels and decrease fat deposit in the liver. CD36 antagonists, including SAB or its metabolites, such as RA and DSS, are useful for these purposes.
• CLUSTER OF DIFFERENTIATION 36 (CD36) AS A THERAPEUTIC TARGET FOR HIV INFECTION
  申请人：INSTITUT CURIE

  公开号：US20150259429A1

  公开（公告）日：2015-09-17

  The present invention concerns new methods for treating HIV infection by using CD36 inhibitors, antibodies or conjugates, and methods for identifying new molecules of interest for treating HIV infection.
• US9283243B2
  申请人：——

  公开号：US9283243B2

  公开（公告）日：2016-03-15